Arrowhead Pharmaceuticals (ARWR) stock gains as company reassures investors about financial obligations required from Sarepta ...

Sarepta Therapeutics' licensing partner Arrowhead Pharmaceuticals said on Wednesday it expects to receive near-term milestone ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), a biopharmaceutical company with a market capitalization of $2.68 billion specializing in RNA interference (RNAi) technology, is on the cusp of a ...

Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price. Read why I am reiterating my bullish rating on ARWR stock.

Shares of Arrowhead Pharmaceuticals, Inc. (ARWR 2.75%) are down 15.4% as of 11:38 a.m. EDT on Monday. The biotech made no announcement, so we can only speculate as to why the stock dropped.

The stock has a market capitalization of $2.63 billion, a P/E ratio of -4.98 and a beta of 0.95. The company has a 50 day moving average price of $21.35 and a 200 day moving average price of $23.94.

Arrowhead plans to seek regulatory clearance in late 2024 to begin clinical trials. In obese and diabetic mice, INHBE siRNA reduced INHBE mRNA expression by 95%, body weight by 19% and fat mass by ...

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) are down 15.4% as of 11:38 a.m. EDT on Monday. The biotech made no announcement, so we can only speculate as to why the stock dropped.